@article {8023,
	title = {Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: A prospective multicenter study},
	journal = {Gynecologic Oncology},
	volume = {95},
	year = {2004},
	note = {Cited By :28Export Date: 21 February 2017},
	month = {2004},
	pages = {695 - 700},
	abstract = {Ovarian germ cell tumors (OGCT) are highly curable when treated with cytoreductive surgery and platinum-based chemotherapy. We evaluated the safety and activity of a 3-day modified bleomycin, etoposide, and cisplatinum (mBEP) regimen in patients with OGCT. Patients with FIGO stages I-IV OGCT were treated with three (stages I-III complete resection) or four cycles (incomplete resection or stage IV) of bleomycin 15 mg iv, etoposide 120 mg/m 2 iv, and cisplatin 40 mg/m 2 iv for 3 days every 3 weeks. Forty-eight patients (14 with dysgerminoma and 34 with non-dysgerminomatous tumors) were included in our study. Most patients had stage I disease (65\%) and complete resection of their tumor (67\%). Twenty percent of patients developed grade 3 or 4 neutropenia with 4 episodes of neutropenic fever. During follow-up (median: 5 years), two patients developed progressive disease including one patient who died. All patients with stage I or II disease and all patients with dysgerminoma remain free of disease. However, 20\% of patients with non-dysgerminomatous tumors stage III or IV experienced progressive disease. The modified 3-day BEP regimen was safe and effective in patients with OGCT. Further improvements are needed for patients with advanced, suboptimally debulked non-dysgerminomatous tumors. {\textcopyright} 2004 Elsevier Inc. All rights reserved.},
	keywords = {BEP, Germ cell, Ovarian carcinoma},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-9944226836\&doi=10.1016\%2fj.ygyno.2004.08.018\&partnerID=40\&md5=b489e2a5964b257b7c68afdd33ef4d59},
	author = {Dimopoulos, M.A. and Papadimitriou, C. and Hamilos, G. and Efstathiou, E. and Vlahos, G. and Rodolakis, A. and Aravantinos, G. and Kalofonos, H. and Kouroussis, C. and Gika, D. and Skarlos, D. and Bamias, A.}
}
